Desquinolinyl Lenvatinib CAS 796848-79-8 Puritas >99.0% (HPLC) Lenvatinib Mesylate Factory intermedia

Description:

1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea

Synonyma: Desquinolinyl Lenvatinib

CAS: 796848-79-8

Puritas: >99.0% (HPLC)

Aspectus: Off-White ad Reddish Brown solidum pulveris

Medium de Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum 1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea
Synonyma Desquinolinyl Lenvatinib;Lenvatinib immunditia 16;Lenvatinib Desquinolinyl Impurity;Lenvatinib immunditia LFS-A;Lenvatinib Mesylate Medium Ⅲ;N-(2-Chloro-4-Hydroxyphenyl)-N'-Cyclopropyl-Urea
CAS Number 796848-79-8
CATTUS Number RF-PI1972
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C10H11ClN2O2
M. Pondus 226.66
Ferveret 364.6±42.0℃
Density 1.43±0.10 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Off-White ad Reddish solidus Pulvis
Puritas / Analysis Methodus >99.0% (HPLC)
Humor (KF) <0.50%
Residere in Ignition <0.20%
una immunditia <0.50%
Totalis immunditias <1.00%
Metalla gravis <10ppm
Infrared Imaginis Conformat ut Structure
NMR Conformat ut Structure
Test Standard Enterprise Standard
Consuetudinem Medium de Mesylate Lenvatinib (CAS: 857890-39-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea, quae etiam Desquinolinyl Lenvatinib nota est, (CAS: 796848-79-8) medium seu immundum Mesylate Lenvatinib (CAS: 857890-39-2).Desquinolinyl Lenvatinib metabolita est de Mesylate Lenvatinib quae viva voce inhibitor est multiplicium receptarum tyrosinae kinasium receptarum VEGF, FGF, SCF receptorum.Lenvatinib medicamento est anti-cancer ad curationem quarundam generis cancri thyroideae, et in potentia ad alias carcinomata.Die 13 Februarii 2015, US FDA approbavit anticancer medicamentum Lenvatinib ad curationem cancri thyreici.Lenvatinib inhibitor enzyme multiplex est, cum possit inhibere VEGFR2 et VEGFR3 (vascularis incrementi endothelialis factor receptor).Nomen artis Lenvatinib est Lenvima.

Epistulam tuam hic scribe et mitte nobis